Videos

National Community Pharmacists Association (NCPA) President Brian Caswell, RPh, said he is incredibly proud of the work community pharmacists have done over the past year.

Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, detail what makes a patient eligible to receive PARP inhibitors as second-line maintenance for the management of ovarian cancer.

Michael Frank, CEO of Revive Therapeutics, and Derrick Welsh, COO of Psilocin Pharma, a division of Revive Therapeutics, discuss clinical research investigating novel treatment targets for psilocybin, such as treatment-resistant depression in patients with cancer.

Pharmacy Times spoke with Dr. Jeffrey Akers, CEO of Pharmaceutical Services at Appalachian Regional Healthcare, about how integrated technology can empower pharmacists to prioritize patient care and safety and can help prevent harmful medication events from occurring.

Jameshia Below, PharmD, assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains how oncologic emergencies present in patients, and how each type can be recognized.

Anna Legreid-Dopp, PharmD, Senior Director of Clinical Guidelines and Quality Improvement at the American Society of Health-System Pharmacists discusses Pfizer’s request to approve their COVID-19 vaccine for children 5 to 11.

Musey discussed the highlights of the new data and how these 2 studies are different than previous studies in this topic area.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses key points to consider regarding co-administration of MDMA, psilocybin, and ketamine with psychiatric medications, such as SSRI or SNRI antidepressants.

In an interview with Pharmacy Times®, Rita Carreón, VP of health at UnidosUS, discusses the impact of the COVID-19 educational mobile tour, launched by AARP and UnidosUS.

Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains what oncologic emergencies are and how they are classified.

Michael Frank, CEO of Revive Therapeutics, discussed the results of a phase 3 trial investigating bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

Peter Lio, MD, discusses patient factors to consider before deciding on a treatment strategy for atopic dermatitis.

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDE, provides an overview of atopic dermatitis.

Two board-certified oncology pharmacists review the importance of PARP inhibitors for second-line maintenance in treating ovarian cancer.

Senator Scott Wiener, discusses the California Senate Bill 519 he co-authored, which is the first and most expansive psychedelic decriminalization bill to go through a state legislature.

In an interview with Pharmacy Times®, Maria Whitman, Global Head of the Pharmaceutical and Biotech Practice at ZS, discusses the FDA’s Project Optimus, the FDA’s new guidance addressing dose optimization issues in oncology clinical trials, and how it has impacted drug manufacturers.

In a Pharmacy Times® interview, Jessica Hui, a researcher and pediatric allergist at National Jewish Health, discussed how increased hand hygiene may be harming the hands of healthcare workers.

Donna Bohannon, RPh, MS, principal scientist at US Pharmacopeia (USP), and Bhumi Khambholja, PharmD, MSHI, project manager of Wisconsin Health Literacy, discuss how to adopt USP standards for labeling to increase health equity.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential adverse effects and drug-drug interactions with psilocybin, MDMA, and ketamine treatment.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what the role of the pharmacist is during the treatment of patients with advanced cutaneous T cell lymphoma.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.

Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, discuss the mechanism of action and efficacy for the 3 PARP inhibitors used to treat patients with ovarian cancer: olaparib, rucaparib, and niraparib.

Bhavesh Shah, RPh, BCOP, provides a brief history of PARP inhibitors in the cancer space, as well as his own introduction to PARP inhibitors.

Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.

Shawn Singh, CEO of VistaGen, discusses how to improve and more effectively treat mental health disorders for returning veterans, who currently account for 20% of all suicides in the United States.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), discusses the SHC’s recently released Flu DRIVE Toolkit, which was designed to help overburdened health systems improve flu vaccination rates among vulnerable populations.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, describes some of the challenges providers face during the treatment of patients with advanced cutaneous T cell lymphoma and how to address them.

A panel of experts in the field of ketamine therapy discuss the role of the pharmacist in this field and the future of ketamine and assisted therapies based on current medical research.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.